Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Rethinking the Standard of Care: orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Rethinking the Standard of Care: ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Rethinking the Standard of Care:, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Rethinking the Standard of Care: in your area.
Frontiers
21.72
NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM
21.39
Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease
20.42
GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read
21.48
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
29.29
💥Soul study group recently shared the result of their study :✔️ Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes @NEJM 🟡 n=9650 🟡 42.4 %had history of CKD 🟡 Majority
23.93
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
26.32
